tradingkey.logo

Tango Therapeutics Inc <TNGX.OQ> expected to post a loss of 35 cents a share - Earnings Preview

ReutersMay 9, 2025 4:41 PM
  • Tango Therapeutics Inc TNGX.OQ TNGX.O is expected to show a rise in quarterly revenue when it reports results on May 12 for the period ending March 31 2025

  • The Boston Massachusetts-based company is expected to report a 3.4% increase in revenue to $6.694 million from $6.47 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Tango Therapeutics Inc is for a loss of 35 cents per share.

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Tango Therapeutics Inc is $10.00​, above​ its last closing price of $1.10. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.33

-0.34

-0.35

Missed

-3.3

Sep. 30 2024

-0.35

-0.37

-0.27

Beat

26.5

Jun. 30 2024

-0.35

-0.34

-0.24

Beat

30.4​

Mar. 31 2024

-0.31

-0.31

-0.35

Missed

-11.9

​​Dec. 31 2023

-0.30

-0.28

-0.32

Missed

-15.2

Sep. 30 2023

-0.34

-0.34

-0.23

Beat

33.3​

Jun. 30 2023

-0.31

-0.34

-0.23

Beat

31.5

Mar. 31 2023

-0.35

-0.35

-0.32

Beat

8.9

This summary was machine generated May 9 at 16:41 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles